Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia [3]

Cancer Genetics and Cytogenetics

Volumn 163, Issue 2, 2005, Pages 189-190

  Ossard Receveur, A ^a   Bernheim, A ^a   Clausse, B ^a   Danglot, G ^a   Fauvet, D ^a   Leon, B ^a   Lozach, F ^a   Bories, D ^b   Brouzes, C ^a   Bourhis, J H ^a   Turhan, A G ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; DNA; IMATINIB;

CANCER RESISTANCE; CHROMOSOME 22; CHROMOSOME 9; CHROMOSOME DELETION; CHROMOSOME DUPLICATION; CHROMOSOME R BAND; CHRONIC MYELOID LEUKEMIA; DICENTRIC CHROMOSOME; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE; GENE AMPLIFICATION; GENE MUTATION; GIEMSA STAIN; HUMAN; LETTER; PHENOTYPE; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN;

ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; DRUG RESISTANCE, NEOPLASM; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; PHILADELPHIA CHROMOSOME; PIPERAZINES; PYRIMIDINES;

EID: 28744448598     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2005.05.004     Document Type: Letter

References (10)

1. J.M. Goldman, and J.V. Melo Chronic myeloid leukemia-advances in biology and new approaches to treatment N Engl J Med 349 2003 1451 1464
2. D.G. Savage, and K.H. Antman Imatinib mesylate- a new oral targeted therapy N Engl J Med 346 2002 683 693
3. N.C. Wolff, and R.L. Ilaria Jr. Establishment of a murine model for therapy-treated chronic myelogenous leukaemia using the tyrosine kinase inhibitor STI571 Blood 98 2001 2808 2816
4. S.G. O'Brien, F. Guilhot, R.A. Larson, I. Gathmann, M. Baccarani, F. Cervantes, J.J. Cornelissen, T. Fischer, A. Hochhaus, T. Hughes, K. Lechner, J.L. Nielsen, P. Rousselot, J. Reiffers, G. Saglio, J. Shepherd, B. Simonsson, A. Gratwohl, J.M. Goldman, H. Kantarjian, K. Taylor, G. Verhoef, A.E. Bolton, R. Capdeville, and B.J. Druker IRIS Investigators. Imatinib compared with Interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia N Engl J Med 348 2003 994 1004
5. F.X. Mahon, M.V. Deininger, B. Schultheis, J. Chabrol Reiffers, J.M. Goldman, and J.V. Melo Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance Blood 96 2002 1070 1079
6. C.B. Gambacorti-Passerini, R.H. Gunby, R. Piazza, A. Galietta, R. Rostagno, and L. Scapozza Molecular mechanisms of resistance to Imatinib in Philadelphia-chromosome-positive leukaemias Lancet Oncol 4 2003 75 85
7. S. Brandford, Z. Rudzki, S. Walsh, A. Grigg, C. Arthur, K. Taylor, R. Hermann, K.P. Lynch, and T.P. Hughes High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance Blood 99 2002 3472 3475
8. G. Marcucci, D. Perrotti, and M.A. Caligiuri Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: Mohamed et al., [Ref. 10] Clin Cancer Res 9 2003 1248 1252
9. A. Hochhaus, and T. Hughes Clinical resistance to imatinib: mechanisms and implications Hematol Oncol Clin North Am 18 2004 641 656
10. A.N. Mohamed, P. Pemberton, J. Zonder, and C.A. Schiffer The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations Clin Cancer Res 9 2003 1333 1337